Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lylia Sivcheva"'
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian
Publikováno v:
HemaSphere, Vol 7, p e216416f (2023)
Externí odkaz:
https://doaj.org/article/4d7243c8e5154d6eb203cf6a0a30256f
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group
Publikováno v:
HemaSphere, Vol 4, Iss 6, p e485 (2020)
Externí odkaz:
https://doaj.org/article/5fda375d5298471dabb1ce29d4ebc970
Autor:
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger
Publikováno v:
Blood. 140:9663-9664
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79c12266681e97de0b25c08f67232056
https://doi.org/10.1182/blood-2022-156889
https://doi.org/10.1182/blood-2022-156889
Autor:
Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, Georgi Mihaylov, Hans Carl Hasselbalch, Lydia Roy, Vera Yablokova, Olga Cerna, Aleksander Skotnicki, Richard Greil, Jiri Schwarz, Vera Stoeva, Lylia Sivcheva, Zvenyslava Masliak, Halyna Pylypenko, Antonia Hatalova, Delia Dima, Jose Miguel Torregrosa-Diaz, Elena Volodicheva, Jean-Jacques Kiladjian, S V Klymenko, Carlos Besses Raebel, Polina Kaplan, Irina Sokolova, Horia Bumbea, Miklos Egyed, Nicoleta Berbec, Barbara Grohmann-Izay, Alexander Myasnikov, Petr Dulicek, Tamila Lysa, Dominik Wolf, Andrei Cucuianu, Christoph Klade, Mihaela Lazaroiu, Maria Soroka-Wojtaszko, Tamás Masszi, Ernst Forjan, Liana Gercheva-Kyuchukova, Franz Bauer, Dorota Krochmalczyk, Árpád Illés, Mikulas Hrubisko, Jolanta Starzak-Gwozdz, Viktor Rossiev
Publikováno v:
The Lancet Haematology. 7:e196-e208
Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. Methods PRO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef767894c3f5dbd8084e8e09eb738e2f
https://doi.org/10.1016/s2352-3026(19)30236-4
https://doi.org/10.1016/s2352-3026(19)30236-4
Autor:
Liana Gercheva-Kyuchukova, Robert Kralovics, Heinz Gisslinger, Miklos Egyed, Árpád Illés, Christoph Klade, Hans Carl Hasselbalch, Lylia Sivcheva, Pencho Georgiev, Kurt Krejcy, Dorota Krochmalczyk, Jiri Mayer, Jean-Jacques Kiladjian, Vera Yablokova, Halyna Pylypenko, Petr Dulíček, Victoria Empson
Publikováno v:
Blood. 138:3660-3660
Introduction: Ropeginterferon alfa-2b (BESREMi®), a novel pegylated interferon with an extended half-life, was approved in Europe for treatment of patients with PV based on results from the phase 3 PROUD-PV and CONTINUATION-PV trials. Ropeginterfero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61f27031d0f1ebd7cc71d47c1c2313b8
https://doi.org/10.1182/blood-2021-152328
https://doi.org/10.1182/blood-2021-152328
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, PROUD-PV Study Group
Publikováno v:
SSRN Electronic Journal.
Background: Ropeginterferon alfa-2b (ropeg) is a novel, mono-pegylated interferon (IFN) for treatment of polycythemia vera (PV). The PROUD-PV/CONTINUATION-PV trial compared ropeg with hydroxyurea (HU), the standard therapy for PV, over three years of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37569d2e3dc4a85c590828407b37f479
https://doi.org/10.2139/ssrn.3426089
https://doi.org/10.2139/ssrn.3426089
Autor:
Lylia Sivcheva, Hans Carl Hasselbalch, Jean-Jacques Kiladjian, Liana Gercheva-Kyuchukova, Christoph Klade, Pencho Georgiev, Victoria Empson, Robert Kralovics, Heinz Gisslinger, Árpád Illés, Miklos Egyed, Jiří Mayer, Halyna Pylypenko, Petr Dulíček, Kurt Krejcy, Dorota Krochmalczyk, Vera Yablokova
Publikováno v:
Blood. 136:33-33
Introduction: Patients with polycythemia vera (PV) require life-long treatment to prevent thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) may ultimately modify the natural history of P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81360b558ff79c6aaadb70b6e1dab942
https://doi.org/10.1182/blood-2020-136973
https://doi.org/10.1182/blood-2020-136973
Autor:
Liana Gercheva-Kyuchukova, Miklos Egyed, Vera Yablokova, Christoph Klade, Viktor Rossiev, Heinz Gisslinger, Halyna Pylypenko, Hans Carl Hasselbalch, Lylia Sivcheva, Petr Dulíček, Kurt Krejcy, Jean-Jacques Kiladjian, Dorota Krochmalczyk, Jiri Mayer, Pencho Georgiev, Robert Kralovics, Árpád Illés
Publikováno v:
Blood. 134:553-553
Introduction: The key treatment goals for polycythemia vera (PV) are to prevent thromboembolic events and minimize the risk of progression, ultimately modifying the natural history of the disease by selectively targeting the malignant clone. In the P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c86d7b21b0f0e43d41dbe1bbfc4760d
https://doi.org/10.1182/blood-2019-122233
https://doi.org/10.1182/blood-2019-122233
Autor:
Kurt Krejcy, Petr Dulíček, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Dorota Krochmalczyk, Viktor Rossiev, Christoph Klade, Liana Gercheva-Kyuchukova, Halyna Pylypenko, Robert Kralovics, Hans Carl Hasselbalch, Miklos Egyed, Jean-Jacques Kiladjian, Árpád Illés, Barbara Grohmann-Izay, Heinz Gisslinger, Pencho Georgiev
Publikováno v:
Blood. 132:579-579
Background: Interferon-alpha (IFN) is being used in myeloproliferative neoplasms (MPNs) since years and remains the only known treatment with disease-modifying potential. Ropeginterferon alfa-2b (Ropeg) is a novel mono-pegylated IFN, with reduced dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98b19f2c5bca29244ad29ef63bcc9b05
https://doi.org/10.1182/blood-2018-99-118715
https://doi.org/10.1182/blood-2018-99-118715